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Abstract
Molecular based in vitro technologies greatly changed the diagnostic approaches in allergy. At present, sensitization
profiles can be dissected according to IgE subsets, which are specific for genuine or cross-reacting components and
potentially dangerous or virtually harmless components. The identification of IgE in components with specific
characteristics has a direct impact on the accuracy of the diagnosis (indeed, it is possible at present to not only
identify the allergen derived from a given allergen source but also the family of molecules to which the patient is
sensitized), on the prognosis of the patient’s allergy, and on the prevention activities to be implemented. More
interestingly, during the last few years, and thanks to the tools of molecular diagnostics, the indications for Allergen
Immunotherapy (AIT) have also be modified, and novel strategies for the selection of the allergens to be
administered have been better defined. Indeed, protocols indicating how Molecular Based Diagnosis (MBD) can be
used to identify the best AIT approach have been recently published. In this review, the rationale for the use of
MBD tools is discussed, and the recent strategies for the choice of allergens to be used in AIT are reported.
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Background
Molecular based diagnosis (MBD) was introduced to “in
vivo” and in “in vitro” allergy diagnostics 15 years ago
[1], and its role is well defined at present [2, 3]. The use
of single components derived from the complex mixture
of proteins contained in the raw allergen extract allows
us to obtain an accurate representation of the IgE
sensitization profile. The IgE-mediated reactivity to spe-
cific components (i.e., proteins that are genuine sensi-
tizers from a single allergen or allergen family) is
suggestive of true sensitization. On the contrary, the
presence of IgE directed to cross-reacting components
(i.e., proteins able to bind IgE within a heterogeneous
group of allergens) suggests sensitization to many differ-
ent allergen sources, which at times is not strictly related
in taxonomy [4]. All these aspects are currently part of
the diagnostic approach [5].
MBD is particularly useful when Allergen Immuno-
therapy (AIT) [6] must be prescribed to patients with re-
spiratory and hymenoptera allergies. An accurate MBD
is substantially useful in patients with food allergies and,
more importantly, in patients with pollen-food syn-
dromes [7], especially when serum IgE directed to cross-
reacting components are involved in the pathogenesis of
the clinical disease [2]. With regards to food allergies,
MBD is even more useful in the identification of food
components that should be avoided in diet. In the light
of these considerations, we will review herein the ration-
ale for the use of MBD in prescribing AIT as well as
when MBD can be profitably applied in clinical practice.
The rationale for the use of MBD in the
prescription of AIT
From a theoretical point of view, the more accurate the
identification of the components evoking the IgE medi-
ated response is, the most appropriate the prescription
of the AIT will be. A paradigmatic example is repre-
sented by IgE sensitization to hymenoptera venoms [6].
In such a case, the allergens (as well as the relevant
components) are well defined, the route of sensitization
is unique, potentially cross-reacting components (such
as carbohydrates CCD) are well known, and hymenop-
tera–allergic patients are generally mono-sensitized.
Moreover, at risk occupations (e.g., beekeepers, gardeners)
* Correspondence: giovannimelioli@gmail.com
1Allergy and Respiratory Diseases, Department of Internal Medicine, IRCCS
San Martino-IST-University of Genoa, L. go R. Benzi 10, 16132 Genoa, Italy
Full list of author information is available at the end of the article
© 2016 Melioli et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Melioli et al. Asthma Research and Practice  (2016) 2:9 
DOI 10.1186/s40733-016-0024-8
and the environment (rural areas, bee/wasp nests) strongly
suggest or support the diagnosis. Additionally, highly spe-
cific reagents can be used for the diagnosis, and purified
allergens can be used in therapy [8]. The situation may be
different with regard to sensitization to common allergens
such as grasses. Hay fever was originally described by
Bostock in 1819, and the causal role of grass pollen was
proven in 1873.
In grass sensitization, the period of pollination (May-
July) usually correlates with symptoms, and symptoms
only rarely occur outside this season.
The molecular analysis of grass pollen (in particular
Phleum pratense derived proteins) showed that two
major (Phl p 1 and Phl p 5), and some minor (Phl p 2,
Phl p 4 etc.) components are detectable [9]. These items
are “specific components” or genuine sensitizers. In
other words, sensitization towards one or more of these
components is associated with a true sensitization to
Phleum pratense. Given that these proteins are related
to the biological structure of grasses, many other plants
can have similar profiles [10]. Thus, one could argue
that AIT based on a single allergen that contains the
most relevant component(s) should also protect from
other allergens belonging to the same families [11, 12].
Different scenarios emerge when the IgE repertoire is
represented by IgE against pan-allergens (e.g., Phl p 12
and Bet v 2, calcium binding proteins Phl p 7 and Bet v
4, and Pathogenesis Related proteins-10 Bet v 1, Cor a 1,
Aln g 1). Immunological cross-reactivity is the result of
the presence of widespread phylogenetically conserved
proteins that show homologous epitopes [13] as well as
the capacity of certain IgE to recognize, with different
affinity, partially homologous proteins derived from dif-
ferent sources. It has been shown that cross-reacting
components are not only less represented in AIT
vaccines [14] but also that the IgE mediated immune-
response to these components is weaker than that to
major components [15–17]. Similar situations occur
with mite and pet allergies.
Results of MBD were described in 2007 and offered an
algorithm to identify which was the best combination of
allergen(s) to be given [18]. More recently, it was shown
that the best clinical results were obtained when AIT
was given to patients sensitized to major components
while unconvincing or controversial results were ob-
served in patients sensitized to minor (or cross-reacting)
components [19].
The clinical experience in the use of MBD for the
prescription of AIT
In recent years, many authors have noted that following
an analysis of the IgE repertoire by MBD, the prescrip-
tion of AIT could be modified. Sastre et al. [20] showed
that in more than 50 % of patients, the allergen
microarray results significantly changed the indication
or the selection of allergens for immunotherapy. This
finding is in agreement with the observations by
Passalacqua et al. [15] AIT was firstly prescribed to 32
out of 318 poly-sensitized patients with respiratory
symptoms. Following MBD, the prescription was chan-
ged in 3 of those patients by adding a new extract, and it
was newly prescribed in 85 additional patients. In an-
other study group, Moreno et al. [21] demonstrated that
within a group of 1263 poly-sensitized patients 922
(73 %) would have been candidates for AIT to treat a
mixture of grass and olive pollens based on available
clinical data and skin prick test results. In 56.8 % of pa-
tients, there was non-coincidence in the composition of
AIT that would be selected before and after investigators
received the in vitro data.
In a large group of pediatric patients, Stringari [22]
showed that after MBD, the SPT-based decision on AIT
prescription or composition was changed in 277 (42 %)
of 651 and 315 (48 %) of 651 children according to the
European or American approach, respectively [23].
Some papers were then published suggesting strategies
to define the composition of AIT starting from the MBD
results (tailored AIT). One, in particular, is interesting
because of the role of the glycidic chains of naturally de-
rived highly purified components compared to standard
recombinant E. coli derived components [24]. In this
work, patients with IgE specific to recombinant genuine
molecules, such as rPhl p 1, rPar j 2, and rOle e 1, are
considered suitable for an AIT treatment because the re-
activity to the component is specifically directed to the
protein core of the allergen. On the contrary, when
MBD results are obtained by the use of natural but
highly purified glycoproteins, such as nCyn d 1, n Cup a
1 or nArt v 1, the presence of a cross-reactivity to CCD
should be ruled out; it is only in this case that the suit-
ability to AIT is accepted. In the same algorithm, a poor
efficacy of AIT is expected in patients characterized by
IgE that is directed to cross-reacting molecules such as
profilins and polcalcins, while better results can be pro-
vided if these IgE specificities are absent.
Concerning the use of certain diagnostics tools to
define AIT, the role of biomarkers is, at present, a new
but strongly effective prospect in many other medical
sciences, such as oncology or infectious diseases. For
example, in a recent publication, FD Popescu revised
potential biomarkers to be used in grass immunotherapy
[25]. Many of these biomarkers can only be evaluated
using research-based methodologies of study, but in the
near future, it will be possible that a small but relevant
panel of molecules will be available in clinical practice.
From this point of view, AIT is the prototype of person-
alized medicine; as described in this review, many scien-
tists are working to further personalize the treatment by
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the use of a more accurate analysis of the IgE repertoire
of patients. If allergology is to follow the evolution of
other medical sciences, biomarkers will be the next step
to be considered and evaluated in controlled clinical tri-
als before they are implemented in practice.
Clinical practice
Could the large number of indications obtained by the
above-mentioned works be translated into the allergists’
practice? At present, the answer is “yes” based on well-
established data and “no” based on the uncertain as-
pects. Until now, no studies have been performed to the
authors’ knowledge that have randomized patients’ AIT
into two separate groups: one receiving an AIT prescrip-
tion based on standard diagnosis and the other by add-
ing MBD. In the second group in particular, rules to be
used to define AIT should be similar those recently
suggested [24]. In the absence of such a controlled study,
the only evidence we have is the work of Schmid-
Grendelmeier [19], who showed in an observational
study that people with genuine sensitizations had better
results than the group with IgE directed to cross-
reacting components. One could argue that such a study
has many intrinsic defects because it is observational
and includes no defined control. Of course, an experi-
mentally controlled and randomized study should be
much more relevant to define the problem.
Despite these uncertain aspects, in the last 8 years,
many authors have suggested indications regarding the
strategy to be followed in prescribing AIT. Valenta et al.
[18] indicated that MBD could support the optimal se-
lection of pollinosis patients for AIT, at least in the
Mediterranean area, and they also suggested what the
central role of MBD is in monitoring the effects of AIT.
The principle was simple and effective. MBD allows the
identification of IgE directed to genuine components,
such as Phl p 1 or Phl p 5, and to the cross-reacting
components Phl p 7 and Phl p 12. The documentation
of a genuine reactivity clearly indicates an AIT directed
to those allergens. The documentation of an IgE reactiv-
ity against cross-reacting components not only explains
the large number of allergens that resulted positive in
SPT and IgE tests, but, in particular, it explains why AIT
avoids allergens whose positivity was only due to a
cross-reaction. These rules were further well defined by
Moreno et al. [21]. With regards to the use of MBD in
the follow-up, Sastre recently described that an adverse
reaction can be associated with a certain “molecular”
profile of patients treated with AIT [26].
Asero recently suggested to use Art v 1, Amb a 1, Par
j 2, Bet v 1, Ole e 1, Pla l 1, Cup a 1, Phl p 1 and Phl p 5
as markers of primary sensitization to mugwort, rag-
weed, pellitory, birch, olive, plantain, cypress, and
Phleum pratense pollens [13]. The presence of reactivity
to these “genuine” components supports the indication
to use AIT. This situation is easy to manage in the large
number of cases in which one or a few allergens react
with IgE. Nevertheless, in poly-sensitized patients, the
situation could be much more complex [27]. To further
indicate this complexity, the European and the American
approaches should be carefully considered, as discussed
recently [6]. In this context, the European school always
suggests not to exceed the number of three different
allergen sources for AIT in the same patient, while the
American school treats patients with a mixture of all the
positive allergens. Of course, advantages and disadvan-
tages are apparent in these two approaches. In addition,
it is evident that MBD was accepted enthusiastically and
used by Europeans but was only barely recognized by
Americans.
Special care should be paid in specific situations that are
different from the previous examples. Even if the case is
very rare, it is possible in a mite allergy that positive SPT
and sIgE are associated with a pure sensitization to tropo-
myosins [28], a component family that shares allergens
between mites, cockroaches, shrimps, snails, etc. AIT for
mites does not contain Der p 10 (the mite tropomyosins)
[29], and for this reason, its administration would be use-
less, at least if an immune reaction to tropomyosins is ex-
pected. Thus, the indication for the correct AIT is
achieved by the collection of an accurate patient history
and by the molecular assay with Der p 1, Der p 2, Der f 1,
Der f 2 and Der p 10.
The introduction of the MBD is also changing the
follow-up of treated patients. Indeed, it has been shown
that severe reactions to olive AIT may occur in patients
sensitized to Ole e 7 and Ole e 9 [30], and other similar
reports are expected in the future.
Asero [13] and others [31] reported that AIT is equally
effective in patients with single or multiple sensitizations
if the administered allergen is carefully selected. Other
authors have suggested simple and probably effective
rules, although this observation has never been demon-
strated with a properly designed clinical study. For ex-
ample, Luengo stated that in the case of sensitization to
the crude extract SPT and/or positive sIgE, AIT indica-
tion would be invisible if all components were negative
because the extracts would be unlikely to contain the
sensitizing molecule [32]. Finally, based on data from
microarray allergen diagnostics (ISAC), Melioli et al
identified 4 different clusters of patients with different
reactivities [12]. The first was characterized only by a re-
activity to genuine molecules, the second to genuine and
few cross-reacting molecules, the third to both genuine
and cross reacting molecules, and the fourth virtually
only to cross-reacting reactive molecules. In an expert
system to support the interpretation of ISAC results
[33], these groups were implemented, and the potential
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capacity to be responsive to AIT is immediately calcu-
lated by the program. With regards to the use of allergen
microarrays in clinics, too many concerns have slowed
down their use in clinical practices, such as the high cost
and the risk of unexpected results. In regards to the cost,
a thorough investigation of the IgE profile using a
single-plexed allergy diagnosis may be even more expen-
sive in polysensitized patients. Unexpected results are
mainly due to an unknown sensitization or to an incom-
plete collection of a patient’s history. However, many
other relevant added values can be obtained from aller-
gen microarrays. In particular, a clear picture of the
sensitization profile is achieved, thus allowing the pa-
tient’s phenotyping; furthermore, the explanation of pos-
sible discrepancies between SPT or specific IgE results
and ISAC are given. Then, multiplexed data allow the
distinction between the sensitization to one or a few
components of a cross-reacting allergen family and, in
many cases, the identification of the first sensitizer is
also suggested. Finally, an exhaustive IgE profile can be
useful in pediatric or adolescent patients to follow-up
the allergenic march at the molecular level [34].
An interesting and poorly explored context for mo-
lecular diagnosis is respiratory occupational allergy. Re-
spiratory occupational allergy is a relevant problem, and
it causes disabilities and socioeconomic consequences
for both the patient and society. It is probably still
underdiagnosed. A correct diagnosis is extremely im-
portant to reduce or limit the consequences of the dis-
ease. In any adult whose asthma or rhinitis begins or
worsens while working, a diagnosis of respiratory occu-
pational allergy should be considered, and a detailed oc-
cupational and medical history should be collected. All
workers should be asked whether symptoms improve on
days away from work or on holidays; positive answers
should lead to further investigation. MBD helps to dis-
tinguish between sensitization to occupational exposures
and cross-reactivities. Some important causes of occupa-
tional allergy are latex or wheat allergies. In a recent re-
view, particular latex molecules [35] have been described
to be major allergens in specific clinical phenotypes,
such as in healthcare workers (Hev b 5 and Hev b 6),
multi-operated patients (Hev b 11), subjects with spina
bifida and patients with the so-called “latex –fruit syn-
drome” (Hev b 6). For example, several wheat proteins
have been identified as causative allergens of occupa-
tional respiratory allergy [36] in bakery workers with
wheat allergies (Tri a 14.). It is possible to test IgE re-
activity in patients with different clinical profiles of
wheat allergy (i.e., food allergy, wheat-dependent
exercise-induced anaphylaxis, and baker’s asthma). In
this regard, because immunotherapy could be attempted
if allergen avoidance is not feasible, the aforementioned
tool would allow a more precise diagnosis [37].
Conclusions
In conclusion, even if we have no formal proofs, a con-
siderable amount of significant evidence has been col-
lected in recent years that shows that MBD has a direct
effect on the strategy of choosing which allergens should
be used in AIT-based clinical trials. At present, the ap-
plication of this evidence is limited to the strategy of
prescription based on European attitudes, but when
regulatory authorities will ask for a more stringent docu-
mentation of the real IgE repertoire of the patients,
MBD will find its ultimate role in the allergist
armamentarium.
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